Company news

Enlivex Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

November 2, 2026

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

October 28, 2026

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

October 27, 2026

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

October 22, 2026

Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

October 19, 2026

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

September 22, 2026

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

July 29, 2026

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

July 28, 2026

Enlivex Announces $400,000,000 Private Placement

July 27, 2026

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

July 19, 2026

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

July 13, 2026

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

July 7, 2026

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

June 23, 2026

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

June 21, 2026

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

June 14, 2026

Enlivex to present quality longevity model powered by prediction markets treasury at Proof of Talk 2026

June 1, 2026

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

May 27, 2026

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

May 26, 2026

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

May 17, 2026

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

May 14, 2026

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

April 30, 2026

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

April 28, 2026

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

April 23, 2026

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

April 20, 2026

Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares

April 8, 2026

Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025

March 26, 2026

Enlivex Reports Full-Year 2025 Results, Profit of $1.23 Billion and Diluted Earnings per Share of $25.48

March 26, 2026

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

March 25, 2026

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

March 23, 2026

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

March 22, 2026

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

January 23, 2026

Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement

November 25, 2025

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

November 24, 2025

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

November 24, 2025

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

November 23, 2025

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

October 28, 2025

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

September 29, 2025

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

September 11, 2025

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

September 9, 2025

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

August 18, 2025

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

August 14, 2025

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

July 28, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

June 10, 2025

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress

April 23, 2025

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

April 21, 2025

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

April 3, 2025

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

March 17, 2025

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

March 4, 2025

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

March 3, 2025

Older news releases →

Decks

The 5 newest of 32 decks. Every deck is listed under its year.